

Synthesis, Characterization and Anti-HIV Evaluation of Some Novel N-[2-(substitutedphenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamides

G. Nagalakshmi*, T.K. Maity and B.C. Maiti

Department of Pharmaceutical Technology, Division of Pharmaceutical Chemistry,
Jadavpur University, Kolkata-700 032, West Bengal, India

*Corres. author: nagalakshmiipharma@gmail.com

Abstract: A series of novel N-[2-(substituted phenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamides (**4a-g**) were synthesized, structurally confirmed by elemental analysis, IR, ¹H NMR and MS spectral analysis, further evaluated for their anti-HIV activity and cytotoxicity in MT-4 cells infected with wild- type HIV-1 strain III_B and HIV-2 strain ROD in comparison with nevirapine (NVP), azidothymidine (AZT), dideoxycytidine (DDC) and dideoxyinosine (DDI), which were used as reference drugs.

Keywords: Benzohydrazide, 1,3-thiazolidin-4-one, 2-sulfanylpropanoic acid, anti-HIV activity, cytotoxicity, MTT assay.

Introduction

HIV-1 (human immunodeficiency virus type 1), a retrovirus of the lentivirus family, is the etiological agent of AIDS [1], an infection characterized by loss of helper T lymphocytes and heavy damage of lymphatic tissue. Global estimates of WHO/UNAIDS showed that 34 million people had been infected with HIV/AIDS at the end of 2010, with 2.7 million getting newly infected with the virus and 1.8 million reported deaths because of AIDS [2]. An estimated 4.0 million people are living with HIV in South-East Asia Region.

The current therapy against AIDS is based on seven classes of anti-HIV drugs: the nucleoside and nucleotide reverse transcriptase inhibitors (indicated as NRTIs and NtRTIs, respectively), the non-nucleoside reverse transcriptase inhibitors (NNRTIs), the protease inhibitors (PIs), the integrase inhibitors (INI), the chemokine (C-C motif) receptor 5 (CCR5) inhibitor and the fusion inhibitor (FI) [3]. NRTIs, NtRTIs, NNRTIs and PIs are combined in the highly active antiretroviral therapy (HAART), which dramatically reduces the incidence of AIDS infection and death.

Despite the fact that HAART combination regimens have significantly decreased the morbidity and mortality among patients with HIV infections, by bringing the viral replication to very low levels, they are still unable to eradicate the virus [4]. So, the continued suppression of the virus by long-term use of the anti-retroviral drugs induces the emergence of drug-resistant viral mutants and the undesirable metabolic side effects. Moreover, when individuals develop resistance to one antiretroviral agent within a class, there is often, but not always, development of cross-resistance to other agents of the same class.

In addition to the facts that millions of people still need HAART treatment, the utility of antiretroviral drugs is further limited by viral resistance and toxicity issues [5]. Unfortunately still there exists no safe, effective vaccine for prevention of HIV either upon pre-exposure or post-exposure prophylaxis. Hence the

current need is availability of more potent, less toxic, easily available, cost-effective therapies not only to treat HIV, but also to prevent its transmission. This is particularly critical in regions of the world such as sub-Saharan Africa, where 67% of the world's HIV infected individuals reside [6].

Reverse Transcriptase (RT) is a key enzyme which plays an essential and multifunctional role in the replication of the human immunodeficiency virus (HIV) [7] and thus represents an attractive target for the development of new drugs useful in AIDS therapy. RT is necessary for the catalytic transformation of single-stranded viral RNA into the double-stranded linear DNA which is integrated into host cell chromosomes [7]. Drug targeted at HIV-RT can be divided into two categories: (i) nucleoside and nucleotide RT inhibitors, and (ii) non-nucleoside RT inhibitors (NNRTIs) [8]. However, in view of the increasing incidence of resistance to current drug regimens and the frequency of adverse events, the development of novel, selective, potent, safe, inexpensive antiviral agents, that are also effective against mutant HIV strains, remains a high priority for medical research.

Antiviral research in the past has primarily focused on the development of nucleoside analogues but of late, non-nucleoside derivatives [9] have also received considerable attention as an alternative therapy. Among the non-nucleoside analogues, 1,3-thiazolidin-4-one is an interesting molecule, which has been found to exhibit diverse biological activities.

The modeling studies carried out on 1*H*, 3*H*-thiazolo[3,4-*a*]benzimidazole (TBZ) analogues (Figure 1) [10], a class of NNRTIs, highlighted the importance of 2,6-dihalo substitution on the phenyl ring at C1 of the nucleus for the activity and also their ability to take "butterfly-like" shape on binding to the receptor site [11]. In this background TBZ analogues were modified by opening imidazole ring of TBZ (Figure 1) to generate 2,3-diaryl-1,3-thiazolidin-4-ones [12] as a new NNRTI scaffold to inhibit HIV-1 RT.



Figure 1. : 1-Aryl-1*H*, 3*H*-thiazolo[3,4-*a*]benzimidazole (TBZ) analogues

1,3-thiazolidin-4-one derivatives have been found to exhibit diverse biological activities such as analgesic [13], anti-inflammatory [14], antiangiogenic [15], anti-HIV [16], *in vitro* anti-*Toxoplasma gondii* [17], antimicrobial [17], antimycobacterial [18], antimalarial [19], trypanocidal [20], antischistosomal [21], anticonvulsant [22], antihistaminic [23], antidiabetic [24], antiarrhythmic [25] and antihypertensive [26] properties.

To search for more specific and novel 1,3-thiazolidin-4-one analogues with a wide therapeutic window and anti-HIV activity, we synthesized some novel N-[2-(substituted phenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamides and evaluated them for their anti-HIV activity and cytotoxicity in MT-4 cells infected with wild-type HIV-1 strain III_B and HIV-2 strain ROD by MTT assay method.


Materials And Methods

Experimental

Benzohydrazide, 4-chlorobenzaldehyde, 2,3-dichlorobenzaldehyde, 2,4-dichlorobenzaldehyde, 4-bromobenzaldehyde, 2-nitrobenzaldehyde, 3-nitrobenzaldehyde, 4-nitrobenzaldehyde and 2-sulfanylpropanoic acid were commercially obtained from Aldrich (Milwaukee, WI). Dry 1,4-dioxane, anhydrous zinc chloride, chloroform, concentrated hydrochloric acid, sodium hydroxide, sodium bicarbonate, dimethyl sulphoxide and silica gel-G were purchased from Merck, Mumbai, India. Melting points were determined in open capillary tubes using Veego melting point apparatus (Model: VMP-DS) and are uncorrected. The purity of the

compounds was checked by thin layer chromatography (TLC) on silica gel-G plates of 0.5 mm thickness using Ethylacetate: Hexane (1:2 v/v) and Benzene: Chloroform (1:1 v/v) as a solvent system and the spots being visualized under iodine vapours. Concentration of the solution after the reaction completion involved the use of a rotary evaporator (Eyela, Japan) operating under reduced pressure. Infrared (IR) spectra were recorded on a Jasco FTIR-4100 spectrophotometer (Jasco Ltd, Tokyo, Japan) using KBr pellet disc technique in the range of 4000-400 cm^{-1} . ^1H NMR spectra were recorded on a Bruker DPX 300 (operating at 300 MHz) NMR spectrometer using CDCl_3 as solvent and TMS as internal standard (chemical shifts in δ , ppm). Spin multiplets are given as s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). Mass spectra (MS) were recorded on a Q-TOF micromass spectrometer by using electrospray ionization (ESI) technique. The elemental analyses (C, H, N) were performed using a Perkin-Elmer 2400 CHN analyzer. Analyses indicated by the symbols of the element were within $\pm 0.4\%$ of the theoretical values. 1,3-thiazolidin-4-one derivatives (**4a-g**) were synthesized as per the reactions outlined in the Scheme 1. The respective physico-chemical characteristics of all the synthesized compounds have been presented in Table 1.

Scheme 1: Synthetic route for the preparation of novel N-[2-(substitutedphenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamides (4a-g**)**



Compound	R
4a	4-Cl
4b	2,3-(Cl) ₂
4c	2,4-(Cl) ₂
4d	4-Br
4e	2-NO ₂
4f	3-NO ₂
4g	4-NO ₂

Synthesis of N'-[(E)-(substitutedphenyl)methylidene]benzohydrazide (**3a-g**)

A mixture of benzohydrazide (**1**) (0.01 mol) and different aromatic aldehydes (**2a-g**) (0.01 mol) (4-chlorobenzaldehyde (**2a**), 2,3-dichlorobenzaldehyde (**2b**), 2,4-dichlorobenzaldehyde (**2c**), 4-bromobenzaldehyde (**2d**), 2-nitrobenzaldehyde (**2e**), 3-nitrobenzaldehyde (**2f**) and 4-nitrobenzaldehyde (**2g**)) were dissolved in absolute ethanol (20 ml) in presence of catalytic amount of conc. hydrochloric acid (0.5 ml) was refluxed for 4-5

h. The progress of the reaction was monitored by TLC using Ethylacetate: Hexane (1:2 v/v) as eluents. After the completion of the reaction, the crystalline product that separated out was filtered, washed with cold water, dried and crystallized from chloroform. Adopting the above procedure seven different schiff's base (**3a-g**) was synthesized. Percentage yield, melting point and Rf value of the synthesized compound (**3a-g**) were determined and presented in Table 1.

Synthesis of N-[2-(substitutedphenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamide (**4a-g**)

A mixture of N'-[(E)-(substitutedphenyl)methylidene]benzohydrazide (**3a-g**) (0.01 mol), 2-sulfanylpropanoic acid (0.015 mol) and anhydrous zinc chloride (0.5 g) in dry 1,4-dioxane (30 ml) was refluxed for 8-10 h. The progress of the reaction was monitored by TLC using Benzene: Chloroform (1:1 v/v) as eluents. After the completion of TLC, 1,4-dioxane was removed under reduced pressure. The final residue obtained was poured into crushed ice and the separated solid was neutralized by adding 10% sodium bicarbonate solution, for the removal of unreacted 2-sulfanylpropanoic acid. The neutralized solid product was filtered, washed with cold water, dried and crystallized from chloroform. Adopting the above procedure seven different 1,3-thiazolidin-4-one analogues (**4a-g**) was synthesized. Percentage yield, melting point and Rf value of the synthesized compound (**4a-g**) were determined and presented in Table 1.

Anti-HIV Activity

Cells:

MT-4 cells were grown and maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 0.1% sodium bicarbonate and 20 µg gentamicin per mL [27].

Evaluation of the antiviral activity of the compounds against HIV-1 strain (III_B) and HIV-2 strain (ROD) in MT-4 cells was performed using the MTT assay as previously described [28]. Stock solutions (10 × final concentrations) of test compounds were added in 25 µL volumes of two series of triplicate wells to allow simultaneous evaluation of their effects on mock- and HIV-infected cells at the beginning of each experiment. Serial 5-fold dilutions of test compounds were made directly in flat-bottomed 96-well microtiter trays using a Biomek 3000 robot (Beckman Instruments, Fullerton, CA). Untreated control HIV- and mock-infected cell samples were included for each sample.

HIV-1 (III_B) [29] or HIV-2 strain (ROD) [30] stock (50 µL) at 100-300 CCID₅₀ (50% cell culture infectious dose) was added to either the infected or mock-infected wells of the microtiter tray. Mock-infected cells were used to evaluate the cytotoxicity of the test compound. Exponentially growing MT-4 cells [31] was centrifuged for 5 min at 1000 rpm and the supernatant was discarded. The MT-4 cells were resuspended at 6×10^5 cells/mL and 50 µL volumes were transferred to the microtiter tray wells. Five days after infection, the viability of mock- and HIV-infected cells was examined spectrophotometrically by the MTT assay.

The MTT assay is based on the reduction of yellow-colored 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Agros Organics, Geel, Belgium) by the enzyme mitochondrial dehydrogenase of metabolically active cells to a blue-purple formazan that can be measured spectrophotometrically [32]. The absorbances were read in an eight-channel computer-controlled photometer (Multiscan Ascent Reader, Labsystems, Helsinki, Finland) at two wavelengths (540 and 690 nm). All data were calculated using the median OD (optical density) value of three wells.

EC₅₀ was defined as the concentration of the drug required for 50% inhibition of virus-induced cytopathicity. CC₅₀ was defined as the concentration of the drug required for reducing the viability of mock-infected cells by 50%. CC₅₀, EC₅₀, and the selectivity index (SI = CC₅₀/ EC₅₀) were then calculated and results analysed (Table 2).

Results And Discussion

Chemistry

In the present study, a series of novel N-[2-(substitutedphenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamides (**4a-g**) were synthesized according to scheme 1. The target compounds (**4a-g**) were prepared from benzohydrazide (**1**) on condensation with different aromatic aldehydes (**2a-g**) in presence of catalytic amount of concentrated hydrochloric acid in absolute ethanol yield N'-[(E)-(substitutedphenyl)methylidene] benzohydrazide (**3a-g**) in 59.8 - 92.03% yields (scheme 1). The physical data of the synthesized compounds (**3a-g**) and (**4a-g**) are presented in Table 1. The purity of the compounds was checked by thin layer chromatography (TLC) showed disappearance of reactant spot on silica gel-G plates of 0.5 mm thickness using Ethylacetate: Hexane (1:2 v/v) and Benzene: Chloroform (1:1 v/v) as a solvent system and the spots being visualized under iodine vapours. The structure of the synthesized compound (**3a-g**) was confirmed on the basis of elemental analysis, FT-IR and ¹H NMR spectral data (Results and discussion part).

The FT-IR spectra of synthesized compounds (**3a-g**) showed absorption bands ranging from 1653.66 - 1644.98 cm⁻¹ for azomethine (>C=N) formation and 1648.84 - 1450.21 cm⁻¹ for C=C ring stretch of phenyl ring, 3084.58 - 3017.09 cm⁻¹ for aromatic C-H and 3389.28 - 3175.22 cm⁻¹ for N-H, secondary amide. The IR spectra of compound (**3a-g**) displayed bands at about 1648.84 - 1623.77 cm⁻¹, 1588.09 - 1524.45 cm⁻¹ and 821.527 - 706.783 cm⁻¹ associated with C=O stretch, amide I band, N-H bend, secondary acyclic amide, amide II band and C-Cl functions. In the IR spectra of compound (**3a-g**), some significant stretching bands due to C-Br, asymmetric ArNO₂, symmetric ArNO₂ and C-N, ArNO₂ were observed at 696.177 cm⁻¹, 1567.84 - 1520.6 cm⁻¹, 1353.78 - 1344.14 cm⁻¹ and 892.88 - 809.956 cm⁻¹, respectively. In the ¹H NMR spectra of compound (**3c**), aromatic (5H) protons appeared as a multiplet (5H) at 7.468 - 7.516 ppm, CONH proton appeared as a singlet (1H) at 9.423 ppm, aromatic (3H) protons appeared as a multiplet (3H) at 7.881 - 7.903 ppm and N=CH proton appeared as a singlet (1H) at 9.004 ppm, which proved the formation of azomethine.

Compound (**3a-g**), which on cyclization with 2-sulfanylpropanoic acid in dry 1,4-dioxane in presence of anhydrous zinc chloride afford the corresponding N-[2-(substitutedphenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamide (**4a-g**) in 57.5 - 80.29% yields (scheme 1). The structure of the synthesized compound (**4a-g**) was established on the basis of elemental analysis, FT-IR, ¹H NMR and mass spectral data (Results and discussion part).

The IR spectrum of compound (**4a-g**) showed strong absorption band at 1777.08 - 1690.3 cm⁻¹ for C=O of 1,3-thiazolidin-4-one, while the band at 2928.38, 2858.95 - 2851.24 cm⁻¹, 1383.68 - 1346.07 cm⁻¹, 785.85 - 696.177 cm⁻¹, 3074.94 - 3021.91 cm⁻¹ and 3386.39 - 3167.51 cm⁻¹, respectively confirms the presence of methyl C-H asymmetric, methyl C-H symmetric, C-N stretch of tertiary aromatic amine, C-S stretch, aromatic C-H and N-H stretch of secondary amide. This is considered to be a strong confirmation for the 1,3-thiazolidin-4-one nucleus formation. The IR spectrum of compound (**4a-g**) displayed bands at about 1694.8 - 1640.16 cm⁻¹, 1583.27 - 1525.42 cm⁻¹, 883.238 - 696.177 cm⁻¹ and 559.255 cm⁻¹ associated with C=O, amide I band, N-H bend, secondary acyclic amide, amide II band, C-Cl and C-Br functions. The IR spectrum of compound (**4a-g**) showed asymmetric ArNO₂ stretching bands at 1589.06 - 1525.42 cm⁻¹, symmetric ArNO₂ at 1397.17 - 1300.75 cm⁻¹, C-N, ArNO₂ at 859.132 - 855.275 cm⁻¹, in addition to stretching band at 1684.52 - 1465.63 cm⁻¹ attributed to C=C of aromatic ring.

In the ¹H NMR spectra of compound (**4c**), aromatic (5H) protons appeared as a multiplet (5H) at 7.459 - 7.564 ppm, CONH proton appeared as a singlet (1H) at 9.681 ppm, C-2 of 1,3-thiazolidin-4-one, N-CH-Ar proton appeared as a singlet (1H) at 6.30 ppm, aromatic (3H) protons appeared as a multiplet (3H) at 7.884 - 7.958 ppm, CH-CH₃ protons appeared as a quartet (1H) at 3.952 - 4.042 ppm and CH-CH₃ protons appeared as a doublet (3H) at 1.647 - 1.656 ppm, which proved the closure of 1,3-thiazolidin-4-one ring. The results of elemental analyses were within ±0.4% of the theoretical values.

Table 1: Physical data of N'-(E)-(substitutedphenyl)methylidene]benzohydrazide (3a-g) and N-[2-(substitutedphenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamide (4a-g)

Compound	Mol. Formula/Mol. Weight	Yield (%)	M.p. (°C)	^a Rf
3a	C ₁₄ H ₁₁ ClN ₂ O/258.70	89.7 (2.32 g)	192.6 - 193.7	0.81
3b	C ₁₄ H ₁₀ Cl ₂ N ₂ O/293.15	88.6 (2.6 g)	198.3 - 199.9	0.89
3c	C ₁₄ H ₁₀ Cl ₂ N ₂ O/293.15	92.03 (2.7 g)	201.2 - 202.1	0.91
3d	C ₁₄ H ₁₁ BrN ₂ O/303.15	82.14 (3.25 g)	209.6 - 211.7	0.85
3e	C ₁₄ H ₁₁ N ₃ O ₃ /269.26	69.82 (1.88 g)	184.5 - 186.2	0.63
3f	C ₁₄ H ₁₁ N ₃ O ₃ /269.26	59.8 (1.61 g)	196.8 - 198.2	0.70
3g	C ₁₄ H ₁₁ N ₃ O ₃ /269.26	76.2 (2.05 g)	235.5 - 236.7	0.65
4a	C ₁₇ H ₁₅ ClN ₂ O ₂ S/346.83	69.4 (2.41 g)	207.3 - 209.4	0.53
4b	C ₁₇ H ₁₄ Cl ₂ N ₂ O ₂ S/381.28	57.5 (2.19 g)	226.1 - 228.4	0.66
4c	C ₁₇ H ₁₄ Cl ₂ N ₂ O ₂ S/381.28	64.2 (2.45 g)	241.3 - 243.1	0.84
4d	C ₁₇ H ₁₅ BrN ₂ O ₂ S/391.28	74.32 (2.91 g)	250 - 252.2	0.44
4e	C ₁₇ H ₁₅ N ₃ O ₄ S/357.38	80.29 (2.87 g)	214 - 216.4	0.41
4f	C ₁₇ H ₁₅ N ₃ O ₄ S/357.38	62.71 (2.24 g)	235.3 - 237.4	0.58
4g	C ₁₇ H ₁₅ N ₃ O ₄ S/357.38	67.1 (2.40 g)	262.4 - 264.2	0.83

^aEthylacetate: Hexane (1:2 v/v) for compound (3a-g) and Benzene: chloroform (1:1 v/v) for compound (4a-g)

N'-(E)-(4-chlorophenyl)methylidene]benzohydrazide (3a)

IR (KBr, cm⁻¹): 3051.8 (aromatic C-H), 1632.45, 1588.09, 1485.88 (C=C aromatic ring), 3178.11 (N-H, secondary amide), 1632.45 (C=O, amide I band), 1653.66, 1632.45 (C=N), 1588.09 (N-H bend, secondary acyclic amide, amide II band), 820.563, 697.141 (C-Cl), 1299.79, 1168.65, 1085.73, 1008.59 (In-plane ring C-H bend); ¹H NMR (CDCl₃, ppm): 7.414-7.441 (m, 5H, Ar-H), 7.763-7.790 (m, 4H, Ar-H), 8.604 (s, 1H, N=CH), 9.909 (br s, 1H, CONH). Anal. calcd. for C₁₄H₁₁ClN₂O: C, 65.00; H, 4.29; N, 10.83. Found: C, 65.12; H, 4.35; N, 10.86.

N'-(E)-(2,3-dichlorophenyl)methylidene]benzohydrazide (3b)

IR (KBr, cm⁻¹): 3026.73 (aromatic C-H), 1647.88, 1553.38, 1450.21, 1409.71 (C=C aromatic ring), 3178.11 (N-H, secondary amide), 1647.88 (C=N, C=O, amide I band), 1553.38 (N-H bend, secondary acyclic amide, amide II band), 784.886, 706.783 (C-Cl), 1292.07, 1185.04, 1154.19, 1045.23 (In-plane ring C-H bend); ¹H NMR (CDCl₃, ppm): 7.566-7.591 (m, 5H, Ar-H), 7.899-7.923 (m, 3H, Ar-H), 9.686 (br s, 1H, CONH), 9.082 (s, 1H, N=CH). Anal. calcd. for C₁₄H₁₀Cl₂N₂O: C, 57.36; H, 3.44; N, 9.56. Found: C, 57.44; H, 3.53; N, 9.6.

N'-(E)-(2,4-dichlorophenyl)methylidene]benzohydrazide (3c)

IR (KBr, cm⁻¹): 3070.12 (aromatic C-H), 1644.98, 1583.27, 1551.45, 1467.56 (C=C aromatic ring), 3234.04 (N-H, secondary amide), 1644.98 (C=N, C=O, amide I band), 1551.45 (N-H bend, secondary acyclic amide, amide II band), 821.527, 693.284 (C-Cl), 1281.47, 1140.69, 1101.15, 1051.98 (In-plane ring C-H bend); ¹H NMR (CDCl₃, ppm): 7.468-7.516 (m, 5H, Ar-H), 7.881-7.903 (m, 3H, Ar-H), 9.423 (br s, 1H, CONH), 9.004 (s, 1H, N=CH). Anal. calcd. for C₁₄H₁₀Cl₂N₂O: C, 57.36; H, 3.44; N, 9.56. Found: C, 57.4; H, 3.49; N, 9.58.

N'-(E)-(4-bromophenyl)methylidene]benzohydrazide (3d)

IR (KBr, cm^{-1}): 3069.16 (aromatic C-H), 1644.98, 1584.24, 1551.45, 1465.23 (C=C aromatic ring), 3235.97 (N-H, secondary amide), 1644.98 (C=N, C=O, amide I band), 1551.45 (N-H bend, secondary acyclic amide, amide II band), 696.177 (C-Br), 1281.47, 1140.69, 1100.19, 1051.98 (In-plane ring C-H bend), 946.877, 862.025, 823.455 (out-of-plane ring C-H bend); ^1H NMR (CDCl_3 , ppm): 7.465-7.595 (m, 5H, Ar-H), 7.887-8.180 (m, 4H, Ar-H), 9.591 (br s, 1H, CONH), 9.006 (s, 1H, N=CH). Anal. calcd. for $\text{C}_{14}\text{H}_{11}\text{BrN}_2\text{O}$: C, 55.47; H, 3.66; N, 9.24. Found: C, 55.54; H, 3.75; N, 9.28.

N'-(E)-(2-nitrophenyl)methylidene]benzohydrazide (3e)

IR (KBr, cm^{-1}): 3084.58 (aromatic C-H), 1623.77, 1524.45, 1436.71 (C=C aromatic ring), 3389.28 (N-H, secondary amide), 1524.45 (N-H bend, secondary acyclic amide, amide II band), 1623.77 (C=N, C=O, amide I band), 942.056, 809.956, 732.817, 699.069 (out-of-plane ring C-H bend), 1524.45 (asymmetric (ArNO_2) ($\text{N}=\text{O}$)₂), 1350.89 (symmetric (ArNO_2) ($\text{N}=\text{O}$)₂), 809.956 (C-N, ArNO_2); ^1H NMR (CDCl_3 , ppm): 7.484-7.702 (m, 9H, Ar-H), 8.737 (s, 1H, N=CH), 9.404 (br s, 1H, CONH). Anal. calcd. for $\text{C}_{14}\text{H}_{11}\text{N}_3\text{O}_3$: C, 62.45; H, 4.12; N, 15.61. Found: C, 62.51; H, 4.18; N, 15.66.

N'-(E)-(3-nitrophenyl)methylidene]benzohydrazide (3f)

IR (KBr, cm^{-1}): 3024.8 (aromatic C-H), 1610.27, 1552.42, 1449.28, 1407.78 (C=C aromatic ring), 3175.22 (N-H, secondary amide), 1552.42 (N-H bend, secondary acyclic amide, amide II band), 1646.91 (C=N, C=O, amide I band), 943.985, 892.88, 784.886, 749.209, 706.783 (out-of-plane ring C-H bend), 1552.42 (asymmetric (ArNO_2) ($\text{N}=\text{O}$)₂), 1353.78, 1292.07 (symmetric (ArNO_2) ($\text{N}=\text{O}$)₂), 892.88 (C-N, ArNO_2); ^1H NMR (CDCl_3 , ppm): 7.414-7.480 (m, 9H, Ar-H), 9.613 (br s, 1H, CONH), 8.605 (s, 1H, N=CH).

N'-(E)-(4-nitrophenyl)methylidene]benzohydrazide (3g)

IR (KBr, cm^{-1}): 3017.09 (aromatic C-H), 1648.84, 1567.84, 1520.6 (C=C aromatic ring), 3182.93 (N-H, secondary amide), 1567.84, 1520.6 (N-H bend, secondary acyclic amide, amide II band), 1648.84 (C=N, C=O, amide I band), 951.698, 841.776, 695.212 (out-of-plane ring C-H bend), 1567.84, 1520.6 (asymmetric (ArNO_2) ($\text{N}=\text{O}$)₂), 1344.14, 1299.79 (symmetric (ArNO_2) ($\text{N}=\text{O}$)₂), 841.776 (C-N, ArNO_2); ^1H NMR (CDCl_3 , ppm): 7.494-7.628 (m, 5H, Ar-H), 9.275 (br s, 1H, CONH), 8.717 (s, 1H, N=CH), 8.173-8.288 (m, 4H, Ar-H). Anal. calcd. for $\text{C}_{14}\text{H}_{11}\text{N}_3\text{O}_3$: C, 62.45; H, 4.12; N, 15.61. Found: C, 62.49; H, 4.16; N, 15.64.

N-[2-(4-chlorophenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamide (4a)

IR (KBr, cm^{-1}): 3069.16 (aromatic C-H), 1640.16, 1566.88, 1529.27, 1488.78 (C=C aromatic ring), 3386.39, 3217.65 (N-H, secondary amide), 1640.16 (C=O, amide I band), 2928.38 (methyl C-H, as CH_3), 2858.95 (methyl C-H, s CH_3), 1349.93 (C-N, tertiary aromatic amine), 823.455, 700.034 (C-Cl), 1566.88, 1529.77 (N-H bend, secondary acyclic amide, amide II band), 700.034 (C-S), 1349.93, 1287.25, 1143.58, 1089.58, 1012.45 (In-plane ring C-H bend); ^1H NMR (CDCl_3 , ppm): 7.382-7.508 (m, 9H, Ar-H), 9.586 (br s, 1H, CONH), 6.301 (s, 1H, N- $\underline{\text{CH}}$ -Ar), 3.997-4.065 (q, 1H, $\underline{\text{CH}}$ - CH_3), 1.635-1.641 (d, 3H, $\text{CH}-\underline{\text{CH}_3}$). ESI-MS: m/z 348 $[\text{M} + 1]^+$. Anal. calcd. for $\text{C}_{17}\text{H}_{15}\text{ClN}_2\text{O}_2\text{S}$: C, 58.87; H, 4.36; N, 8.08. Found: C, 58.91; H, 4.42; N, 8.10.

N-[2-(2,3-dichlorophenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamide (4b)

IR (KBr, cm^{-1}): 3071.08 (aromatic C-H), 1664.27, 1644.02, 1599.66, 1567.84, 1528.31, 1486.85, 1403.92 (C=C aromatic ring), 3386.39, 3218.61 (N-H, secondary amide), 1644.02 (C=O, amide I band), 1772.26 (C=O, thiazolidin-4-one), 1349.93 (C-N, tertiary aromatic amine), 883.238, 821.527, 732.817, 700.998 (C-Cl), 732.817, 700.998 (C-S), 1349.93, 1285.32, 1142.62, 1089.58, 1009.55 (In-plane ring C-H bend), 1567.84, 1528.31 (N-H bend, secondary acyclic amide, amide II band); ^1H NMR (CDCl_3 , ppm): 7.212-7.262 (m, 5H, Ar-H), 9.647 (br s, 1H, CONH), 6.301 (s, 1H, N- $\underline{\text{CH}}$ -Ar), 3.997-4.065 (q, 1H, $\underline{\text{CH}}$ - CH_3), 1.657-1.665 (d, 3H, $\text{CH}-\underline{\text{CH}_3}$), 7.886-7.962 (m, 3H, Ar-H). ESI-MS: m/z 381 $[\text{M}]^+$. Anal. calcd. for $\text{C}_{17}\text{H}_{14}\text{Cl}_2\text{N}_2\text{O}_2\text{S}$: C, 53.55; H, 3.70; N, 7.35. Found: C, 53.62; H, 3.78; N, 7.38.

N-[2-(2,4-dichlorophenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamide (4c)

IR (KBr, cm^{-1}): 3068.19 (aromatic C-H), 1684.52, 1645.95, 1612.2, 1583.27, 1551.45, 1465.63 (C=C aromatic ring), 3232.11 (N-H, secondary amide), 1645.95 (C=O, amide I band), 1777.08, 1710.55 (C=O,

thiazolidin-4-one), 1349.93 (C-N, tertiary aromatic amine), 2928.38 (methyl C-H, as CH₃), 862.025, 822.491, 781.029, 696.177, 621.931 (C-Cl), 696.177, 621.931 (C-S), 1382.71, 1349.93, 1279.54, 1211.08, 1138.76, 1099.23, 1048.12 (In-plane ring C-H bend), 944.949, 862.025, 822.491, 781.029, 696.177, 621.931 (out-of-plane ring C-H bend), 1583.27, 1551.45 (N-H bend, secondary acyclic amide, amide II band), 1465.63 (methyl C-H bend, as CH₃); ¹H NMR (CDCl₃, ppm): 7.459-7.564 (m, 5H, Ar-H), 9.681 (br s, 1H, CONH), 6.30 (s, 1H, N-CH-Ar), 3.952-4.042 (q, 1H, CH-CH₃), 1.647-1.656 (d, 3H, CH-CH₃), 7.884-7.958 (m, 3H, Ar-H). MS: *m/z* 382 [M + 1]⁺. Anal. calcd. for C₁₇H₁₄Cl₂N₂O₂S: C, 53.55; H, 3.70; N, 7.35. Found: C, 53.59; H, 3.74; N, 7.39.

N-[2-(4-bromophenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamide (4d)

IR (KBr, cm⁻¹): 3074.94 (aromatic C-H), 1646.91, 1583.27, 1466.6 (C=C aromatic ring), 3234.04 (N-H, secondary amide), 1646.91 (C=O, amide I band), 1690.3 (C=O, thiazolidin-4-one), 1383.68 (C-N, tertiary aromatic amine), 2928.38 (methyl C-H, as CH₃), 559.255 (C-Br), 785.85, 697.141 (C-S), 1383.68, 1279.54, 1209.15, 1139.72, 1100.19, 1051.01 (In-plane ring C-H bend), 947.842, 863.953, 821.527, 785.85, 697.141 (out-of-plane ring C-H bend), 1583.27 (N-H bend, secondary acyclic amide, amide II band), 1466.6 (methyl C-H bend, as CH₃); ¹H NMR (CDCl₃, ppm): 7.264-7.419 (m, 5H, Ar-H), 9.661 (br s, 1H, CONH), 6.302 (s, 1H, N-CH-Ar), 3.968-4.045 (q, 1H, CH-CH₃), 1.635-1.658 (d, 3H, CH-CH₃), 7.891-7.967 (m, 4H, Ar-H). ESI-MS: *m/z* 392 [M + 1]⁺. Anal. calcd. for C₁₇H₁₅BrN₂O₂S: C, 52.18; H, 3.86; N, 7.16. Found: C, 52.23; H, 3.93; N, 7.14.

N-[5-methyl-2-(2-nitrophenyl)-4-oxo-1,3-thiazolidin-3-yl]benzamide (4e)

IR (KBr, cm⁻¹): 3021.91 (aromatic C-H), 1649.8, 1567.84, 1525.42, 1444.42 (C=C aromatic ring), 3167.51 (N-H, secondary amide), 1649.8 (C=O, amide I band), 1715.37 (C=O, thiazolidin-4-one), 1346.07 (C-N, tertiary aromatic amine), 2851.24 (methyl C-H, s CH₃), 741.496, 699.069 (C-S), 1567.84, 1525.42 (asymmetric (ArNO₂) (N=O)₂), 1346.07, 1300.75 (symmetric (ArNO₂) (N=O)₂), 855.275 (C-N, ArNO₂), 1444.42 (methyl C-H bend, as CH₃), 963.269, 855.275, 787.779 (out-of-plane ring C-H bend), 1567.84, 1525.42 (N-H bend, secondary acyclic amide, amide II band); ¹H NMR (CDCl₃, ppm): 7.464-7.595 (m, 5H, Ar-H), 9.800 (br s, 1H, CONH), 6.312 (s, 1H, N-CH-Ar), 3.968-4.044 (q, 1H, CH-CH₃), 1.631-1.638 (d, 3H, CH-CH₃), 7.699-7.820 (m, 4H, Ar-H). ESI-MS: *m/z* 358 [M + 1]⁺. Anal. calcd. for C₁₇H₁₅N₃O₄S: C, 57.13; H, 4.23; N, 11.76. Found: C, 57.19; H, 4.29; N, 11.79.

N-[5-methyl-2-(3-nitrophenyl)-4-oxo-1,3-thiazolidin-3-yl]benzamide (4f)

IR (KBr, cm⁻¹): 3024.8 (aromatic C-H), 1649.8, 1604.48, 1567.84, 1525.42, 1444.42 (C=C aromatic ring), 3179.08 (N-H, secondary amide), 1694.8 (C=O, amide I band), 1715.37 (C=O, thiazolidin-4-one), 1346.07, 1301.72 (C-N, tertiary aromatic amine), 2855.1 (methyl C-H, s CH₃), 740.531, 699.069 (C-S), 1567.84, 1525.42 (asymmetric (ArNO₂) (N=O)₂), 1346.07, 1301.72 (symmetric (ArNO₂) (N=O)₂), 855.275 (C-N, ArNO₂), 964.233, 855.275, 787.779 (out-of-plane ring C-H bend), 1567.84, 1525.42 (N-H bend, secondary acyclic amide, amide II band), 1444.42 (methyl C-H bend, as CH₃); ¹H NMR (CDCl₃, ppm): 7.266-7.280 (m, 4H, Ar-H), 7.330-7.598 (m, 5H, Ar-H), 9.93 (br s, 1H, CONH), 6.302 (s, 1H, N-CH-Ar), 3.970-4.045 (q, 1H, CH-CH₃), 1.632-1.639 (d, 3H, CH-CH₃). Anal. calcd. for C₁₇H₁₅N₃O₄S: C, 57.13; H, 4.23; N, 11.76. Found: C, 57.21; H, 4.31; N, 11.75.

N-[5-methyl-2-(4-nitrophenyl)-4-oxo-1,3-thiazolidin-3-yl]benzamide (4g)

IR (KBr, cm⁻¹): 3073.01 (aromatic C-H), 1646.91, 1583.27, 1466.6 (C=C aromatic ring), 3232.11 (N-H, secondary amide), 1646.91 (C=O, amide I band), 1716.34 (C=O, thiazolidin-4-one), 1383.68 (C-N, tertiary aromatic amine), 2928.38 (methyl C-H, as CH₃), 697.141 (C-S), 1583.27 (asymmetric (ArNO₂) (N=O)₂), 1383.68, 1279.54 (symmetric (ArNO₂) (N=O)₂), 863.953 (C-N, ArNO₂), 946.877, 863.953, 821.527 (out-of-plane ring C-H bend), 1583.27 (N-H bend, secondary acyclic amide, amide II band), 1466.6 (methyl C-H bend, as CH₃); ¹H NMR (CDCl₃, ppm): 7.267-7.281 (m, 4H, Ar-H), 7.320-7.597 (m, 5H, Ar-H), 10.022 (br s, 1H, CONH), 6.310 (s, 1H, N-CH-Ar), 3.970-4.044 (q, 1H, CH-CH₃), 1.630-1.638 (d, 3H, CH-CH₃). ESI-MS: *m/z* 358 [M + 1]⁺. Anal. calcd. for C₁₇H₁₅N₃O₄S: C, 57.13; H, 4.23; N, 11.76. Found: C, 57.17; H, 4.27; N, 11.80.

Anti-HIV Activity

All the newly synthesized N-[2-(substituted phenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamides (**4a-g**) were evaluated for their anti-HIV activity and cytotoxicity in MT-4 cell cultures infected with wild-type HIV-1 strain III_B and HIV-2 strain ROD in comparison with nevirapine (NVP), azidothymidine (AZT), dideoxycytidine (DDC) and dideoxyinosine (DDI), which were used as reference drugs. The results, expressed as EC₅₀ (50% Effective concentration), CC₅₀ (50% cytotoxic concentration) and SI (selectivity index given by the CC₅₀/EC₅₀ ratio), are summarized in Table 2.

The experimental results indicated that none of the synthesized compounds inhibited the replication of HIV-1 (III_B) and HIV-2 (ROD) in MT-4 cell cultures at subtoxic concentrations.

Based on the experience with this type of molecules, 1,3-thiazolidin-4-one are considered to act on the allosteric site of HIV-RT [33], and a certain degree of flexibility might be required for binding to HIV-1 RT. The absence of anti-HIV potency in most of the compounds was possibly due to their inability to exist in butterfly-like conformation.

Table 2: Anti-HIV activity, cytotoxicity and selectivity index of N-[2-(substituted phenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamides in MT-4 cells (4a-g)

Compound	EC ₅₀ (µg/ml) ^a		CC ₅₀ (µg/ml) ^b		Selectivity index (SI) ^c	
	HIV-1 (III _B)	HIV-2 (ROD)	HIV-1 (III _B)	HIV-2 (ROD)	HIV-1 (III _B)	HIV-2 (ROD)
4a	>36.45	>36.45	36.45	36.45	<1	<1
4b	>37.38	>37.38	37.38	37.38	<1	<1
4c	>16.20	>16.20	16.20	16.20	<1	<1
4d	>23.23	>23.23	23.23	23.23	<1	<1
4e	>62.05	>62.05	62.05	62.05	<1	<1
4f	>54.18	>54.18	54.18	54.18	<1	<1
4g	>45.18	>45.18	45.18	45.18	<1	<1
Nevirapine	0.050	>4.00	>4.00	>4.00	>80	<1
Azidothymidine (AZT)	0.0022	0.00094	>25.00	>25.00	>11587	>26731
Dideoxycytidine (DDC)	0.16	0.19	>20.00	>20.00	>127	>108
Dideoxyinosine (DDI)	2.09	3.78	>50.00	>50.00	>24	>13

^aEC₅₀: Effective concentration or compound concentration achieving 50% inhibition of HIV-1-induced cytopathicity in MT-4 infected cell cultures.

^bCC₅₀: Cytotoxic concentration or compound concentration that reduces the normal uninfected MT-4 cell viability by 50%.

^cSI: Selectivity index: ratio CC₅₀/EC₅₀. The SI values: ×1 stand for 1 or <1.

Conclusion

In conclusion, we synthesized a series of novel N-[2-(substituted phenyl)-5-methyl-4-oxo-1,3-thiazolidin-3-yl]benzamides (**4a-g**), which were structurally confirmed by IR, ¹H NMR, elemental and MS spectral analysis and evaluated for their inhibition of HIV [HIV-1 (III_B) and HIV-2 (ROD)]-induced cytopathogenicity in MT-4 cell culture. The results indicated that none of the compounds were active against HIV-1 and HIV-2 replication. Although the pharmacological results are not very encouraging, this study provides useful information to further design new anti-HIV agents.

Acknowledgements

The authors are thankful to Jadavpur University, Kolkata for providing the necessary facilities to carry out this research work. The authors express their sincere thanks and acknowledge the financial support from All India Council for Technical Education (AICTE), Quality Improvement Programme, New Delhi, India, for the financial assistance provided to carry out this research work. The authors are also thankful to the Director,

Indian Institute of Chemical Biology (IICB), Kolkata for providing spectral data. The authors would like to thank Kristien Erven, Rega Institute, for her excellent technical assistance in performing the antiviral activity assays.

References

1. Rotili D., Tarantino D., Artico M., Nawrozkij M.B., Gonzalez-Ortega E., Clotet B., Samwele A., Este J.A., Maga G. and Mai A., Diarylpyrimidine-dihydrobenzoyloxopyrimidine hybrids: New, wide spectrum anti-HIV-1 agents active at (sub)-nanomolar levels, *J. Med. Chem.*, 2011, 54, 3091-3096.
2. WHO/UNAIDS AIDS Epidemic Update. December 2009.
3. Este J.A. and Cihlar T., Current status and challenges of antiretroviral research and therapy, *Antiviral Res.*, 2010, 85, 25-33.
4. Broder S., The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic, *Antiviral Res.*, 2010, 85, 1-18.
5. Hawkins T., Understanding and managing the adverse effects of antiretroviral therapy, *Antiviral Res.*, 2010, 85, 201-209.
6. Granich R., Crowley S., Victoria M., Lo Y.R., Souteyrand Y., Dye C., Gilks C., Guerrma T., De Cock K.M. and Williams B., Highly active antiretroviral treatment for the prevention of HIV transmission, *J. Int. AIDS Soc.*, 2010, 13, 1-8.
7. Jonckheere H., Anne J. and De Clercq E., The HIV-1 reverse transcription (RT) process as target for RT inhibitors, *Med. Res. Rev.*, 2000, 20, 129-154.
8. Mugnaini C., Alongi M., Togninelli A., Gevariya H., Brizzi A., Manetti F., Bernardini C., Angeli L., Tafi A., Bellucci L., Corelli F., Massa S. and Maga G., Samuele A., Facchini M., Clotet-Codina I., Armand-Ugon M., Este J.A., Botta M., Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants, *J. Med. Chem.*, 2007, 50, 6580-6595.
9. Rashad A.E., Hegab M.I., Abdel-Megeid R.E., Micky J.A. and Abdel-Megeid F.M., Synthesis and antiviral evaluation of some new pyrazole and fused pyrazolopyrimidine derivatives, *Bioorg. Med. Chem.*, 2008, 16, 7102-7106.
10. Chimirri A., Grasso S., Monforte P., Rao A., Zappala M., Monforte A.M., Pannecouque C., Witvrouw M., Balzarini J. and De Clercq E., Synthesis and biological activity of novel 1*H*, 3*H*-thiazolo[3,4-*a*]benzimidazoles: nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors, *Antiviral Chem. Chemother.*, 1999, 10, 211-217.
11. Barreca M.L., Chimirri A., Carotli A., Monforte A.M., Pellegrini Calace M. and Rao M., Comparative molecular field analysis (CoMFA) and docking studies of nonnucleoside HIV-1 RT inhibitors (NNRTIs), *Bioorg. Med. Chem.*, 1999, 7, 2283-2292.
12. Barreca M.L., Balzarini J., Chimirri A., De Clercq E., De Luca L., Holtje H.D., Holtje M., Monforte A.M., Monforte P., Pannecouque C., Rao A. and Zappala M., Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents, *J. Med. Chem.*, 2002, 45, 5410-5413.
13. Vigorita M.G., Ottana R., Monforte F., Maccari R., Trovato A., Monforte M.T. and Taviano M.F., Synthesis and anti-inflammatory, analgesic activity of 3,3'-(1,2-ethanediyl)-bis[2-aryl-4-thiazolidinone] chiral compounds. Part 10, *Bioorg. Med. Chem. Lett.*, 2001, 11, 2791-2794.
14. Geronikaki A.A., Lagunin A.A., Hadjipavlou-Litina D.I., Eleftheriou P.T., Filimonov D.A., Poroikov V.V., Alam I. and Saxena A.K., Computer-Aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition, *J. Med. Chem.*, 2008, 51, 1601-1609.
15. Chandrappa S., Chandru H., Sharada A.C., Vinaya K., Anandakumar C.S., Thimmegowda N.R., Nagegowda P., Karunakumar M. and Rangappa K.S., Synthesis and *in vivo* anticancer and antiangiogenic effects of novel thioxothiazolidin-4-one derivatives against transplantable mouse tumor, *Med. Chem. Res.*, 2010, 19, 236-249.
16. Balzarini J., Krzesinska B.O., Maurin J.K. and Orzeszko A., Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones, *Eur. J. Med. Chem.*, 2009, 44, 303-311.
17. de Aquino T.M., Liesen A.P., da Silva R.E.A., Lima V.T., Carvelho L.C.S., de Faria A.R., de Araujo J.M., de Lima J.G., Alves A.J., de Melo E.J.T. and Goes A.J.S., Synthesis, anti-*Toxoplasma gondii* and

- antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids, *Bioorg. Med. Chem.*, 2008, 16, 446-456.
18. Babaoglu K., Page M.A., Jones V.C., Mc Neil M.R., Dong C., Naismith J.H. and Lee R.E., Novel inhibitors of an emerging target in *Mycobacterium tuberculosis*; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis, *Bioorg. Med. Chem. Lett.*, 2003, 13, 3227-3230.
 19. Singh B., Mehta D., Baregama L.K. and Talesara G.L., Synthesis and biological evaluation of 7-*N*-(*n*-alkoxyphthalimido)-2-hydroxy-4-aryl-6-aryliminothiazolidino[2,3-*b*] pyrimidines and related compounds, *Indian J Chem.*, 2004, 43B, 1306-1313.
 20. Smith T.K., Young B.L., Denton H., Hughes D.L. and Wagner G.K., First small molecular inhibitors of *T. brucei* dolichophosphate mannose synthase (DPMS), a validated drug target in African sleeping sickness, *Bioorg. Med. Chem. Lett.*, 2009, 19, 1749-1752.
 21. Ottana R., Maccari R., Ciurleto R., Vigorita M.G., Panico A.M., Cardile V., Garufi F., Ronsivalle S., Synthesis and *in vitro* evaluation of 5-arylidene-3-hydroxyalkyl-2-phenylimino-4-thiazolidinones with antiproliferative activity on human chondrocyte cultures, *Bioorg. Med. Chem.*, 2007, 15, 7618-7625.
 22. Ulusoy N., Ergenc N., Ekinci A.C. and Ozer H., Synthesis and anticonvulsant activity of some new arylidenehydrazides and 4-thiazolidinones, *Monatshefte fur Chemie.*, 1996, 127, 1197-1202.
 23. Diurno M.V., Mazzoni O., Correale G., Monterrey I.G., Calignano A., Rana G.L. and Bolognese A., Synthesis and structure-activity relationships of 2-(substitutedphenyl)-3-[3-(*N,N*-dimethylamino)propyl]-1,3-thiazolidin-4-ones acting as H₁-histamine antagonists, *IL Farmaco.*, 1999, 54, 579-583.
 24. Shingalapur R.V., Hosamani K.M., Keri R.S. and Hugar M.H., Derivatives of benzimidazole pharmacophore: synthesis, anticonvulsant, antidiabetic and DNA cleavage studies, *Eur. J. Med. Chem.*, 2010, 45, 1753-1759.
 25. Jackson C.M., Blass B., Coburn K., Djandjighian L., Fadayel G., Fluke A.J., Hodson S.J., Janusz J.M., Murawskej M., Ridgeway J.M., White R.E., Wu S., Evaluation of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias, *Bioorg. Med. Chem. Lett.*, 2007, 17, 282-284.
 26. Bhandari S.V., Bothara K.G., Patil A.A., Chitra T.S., Sarkate A.P., Gore S.T., Dangre S.C. and Kanchane C.V., Design, Synthesis and pharmacological screening of novel antihypertensive agents using hybrid approach, *Bioorg. Med. Chem.*, 2009, 17, 390-400.
 27. Asaftei S. and De Clercq E., "Viologen" Dendrimers as antiviral agents: the effect of charge number and distance, *J. Med. Chem.*, 2010, 53, 3480-3488.
 28. Pannecouque C., Daelemans D. and De Clercq E., Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: Revisited 20 years later, *Nature Protocols.*, 2008, 3, 427-434.
 29. Popovic M., Sarngadharan M.G., Read E. and Gallo R.C., Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patient with AIDS and Pre-AIDS, *Science.*, 1984, 224, 497-500.
 30. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Grest J., Dautet C., Axler-Blin C., Vezinet-Brun F., Rouzioux C., Rozenbaum W. and Montagnier L., Isolation of a T-lymphotropic retrovirus from patient at risk for AIDS. *Science.*, 1983, 220, 868-871.
 31. Miyoshi I., Taguchi H., Kobonishi I., Yoshimoto S., Ohtsuki Y., Shiraishi Y., Akagi T. and Type C., Virus producing cell lines derived from adult T cell leukaemia, *Gann Monogr.*, 1982, 28, 219-228.
 32. Massari S., Daelemans D., Barreca M.L., Knezevich A., Sabatini S., Ceccnetti V., Marcello A., Pannecouque C. and Tabarrini O.A., 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication, *J. Med. Chem.*, 2010, 53, 641-648.
 33. Karrakus S., Kucukguzel S.G., Kucukguzel I., De Clercq E., Pannecouque C., Andrei G., Snoeck R., Sahin F. and Bayrak O.F., Synthesis, antiviral and anticancer activity of some novel thioureas derived from *N*-(4-nitro-2-phenoxyphenyl)-methanesulfonamide, *Eur. J. Med. Chem.*, 2009, 44, 3591-3595.
